Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran)

Thrombosis and Haemostasis

Volumn 87, Issue 4, 2002, Pages 557-562

  Mattsson, Christer ^a   Bjorkman J A ^a   Abrahamsson, T ^a   Nerme, V ^a   Schatteman, K ^a   Leurs, J ^a   Scharpe S ^a   Hendriks, D ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

CPU assay; Melagatran; TAFI; Thrombin inhibitor; Thrombolysis

Indexed keywords

3 (2 GUANIDINOETHYL) 2 MERCAPTOSUCCINIC ACID; ALTEPLASE; CARBOXYPEPTIDASE B; MELAGATRAN; POTATO TUBER CARBOXYPEPTIDASE INHIBITOR; PRO CARBOXYPEPTIDASE U; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERIAL BLOOD; ARTERIAL CIRCULATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HEART VENTRICLE FIBRILLATION; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS;

EID: 0036214635     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613049     Document Type: Article

References (27)

1. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N
2. Purification and characterization of a new arginine carboxypeptidase in human serum
3. TAFI, or plasma pro-carboxypeptidase B couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
4. Isolation, molecular cloning, and partial characterisation of a novel carboxypeptidase B from human plasma
5. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
6. Carboxypeptidase U inhibitors increase the rate of fibrinolysis in a rat DIC model
7. Inducible carboxypeptidase activity. A role in clot lysis in vivo
8. A carboxypeptidase inhibitor markedly improves the potency of t-PA in vivo
9. A novel approach to arterial thrombolysis
10. Antithrombotic activity of inogatran, a new low molecular weight thrombin inhibitor, in a closed-chest porcine model of coronary artery thrombosis
11. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator improves thrombolysis
12. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis
13. Effects of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
14. A spiral wire technique for producing gradually occlusive coronary thrombosis
15. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin
16. Clot-selective coronary thrombolysis with tissue-type plasminogen activator
17. Measurement of procarboxypeptidase U in human plasma
18. Assay of carboxypeptidase N activity in serum by liquid- chromatographic determination of hippuric acid
19. Assessment of AUC
20. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis
21. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: A comparison with heparin in a canine model of coronary artery thrombosis
22. Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone
23. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis
24. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model
25. Enhancement of rabbit jugular vein thrombolysis by neutralisation of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor
26. The combined inhibition of carboxypeptidase U and thrombin increases synergistically the rate of fibrinolysis in a rat DIC model
27. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin-independent inhibitors